Asston Pharmaceuticals to shift registered office, buy property in Oct 13 board meet

scanx
Reviewed by
Shriram SScanX News Team
Key Highlights
  • Board meeting scheduled for October 13, 2026
  • Agenda includes shifting registered office address
  • Proposal to acquire immovable property via bank auction
  • Filing made under SEBI LODR Regulation 29(1)
powered bylight_fuzz_icon
52837738

*this image is generated using AI for illustrative purposes only.

Asston Pharmaceuticals Limited will convene a Board of Directors meeting on Tuesday, October 13, 2026. The agenda includes approving the relocation of the company's registered office and the acquisition of immovable property through a bank or financial institution auction.

Key Agenda Items

The company filed an intimation with BSE Limited under Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The specific matters to be considered are:

  • Shifting the registered office address of the company.
  • Acquiring immovable property through Bank/Financial Institution Auction.
  • Other incidental matters.

Meeting Details

Detail Information
Meeting Date October 13, 2026
Filing Date October 6, 2026
Regulatory Reference SEBI LODR Regulation 29(1)
Current Registered Office Navi Mumbai, Maharashtra

The current registered office is located at Balaji Bhavan, Sector-11 CBD Belapur, Navi Mumbai. The proposal to shift this address suggests a potential operational or strategic realignment, though the new location has not been disclosed in the filing.

Corporate Governance

The intimation was signed by Rishi Upadhaya, Company Secretary & Compliance Officer. The company, formerly known as Asston Pharmaceuticals Private Limited, continues to operate under its public limited structure as per the filing details provided to the stock exchange.

Historical Stock Returns for Asston Pharmaceuticals

1 Day5 Days1 Month6 Months1 Year5 Years
-0.66%-1.67%-11.46%+24.81%0.0%-22.09%

How might the relocation of the registered office impact Asston Pharmaceuticals' operational costs and regional tax incentives?

What is the intended strategic use of the immovable property acquired through the bank auction, and how will it be financed?

Could the property acquisition signal a shift in business focus from pure pharmaceutical operations to real estate or asset holding?

like18
dislike

Asston Pharmaceuticals AGM sees 100% approval for all resolutions

scanx
Reviewed by
Anirudha BScanX News Team
Key Highlights
  • All six resolutions at Asston Pharmaceuticals' 7th AGM passed with 100% votes in favour
  • Promoter group abstained from voting on director remuneration hikes, leaving public shareholders to decide
  • M/s Panchal S K & Associates ratified as statutory auditors following board appointment
  • Total valid votes for financial statement adoption stood at 4,597,509
powered bylight_fuzz_icon
52213891

*this image is generated using AI for illustrative purposes only.

Asston Pharmaceuticals Limited concluded its seventh Annual General Meeting (AGM) on September 29, 2026, with shareholders approving all six agenda items unanimously. The final voting results, submitted to BSE Limited on October 1, 2026, confirm that every resolution received 100% votes in favour, with zero votes against or invalid.

The meeting, conducted via Video Conferencing/Other Audio Visual Means, saw shareholders vote on critical corporate resolutions including the appointment of statutory auditors and revisions to director remuneration. Key approvals included the adoption of audited financial statements for the fiscal year ended March 31, 2026, and the reappointment of Mr. Ashish Narayan Sakalkar as Managing Director.

Resolutions Passed at the AGM

Shareholders voted on both ordinary and special resolutions through remote e-voting and instant voting during the meeting. The following table summarizes the key agenda items put to vote and their outcomes:

Item No. Agenda Description Type Votes in Favour Votes Against
1 Adopt audited financial statements for FY26 Ordinary 4,597,509 0
2 Appoint Mr. Ashish Narayan Sakalkar (MD) retiring by rotation Ordinary 2,744,653 0
3 Approve appointment of M/s Panchal S K & Associates as statutory auditors Ordinary 4,597,509 0
4 Approve increase in remuneration of Mr. Ashish Narayan Sakalkar Special 285,029 0
5 Approve increase in remuneration of Mrs. Saili Jayaram More Special 285,029 0
6 Approve increase in remuneration of Mr. Sachin Chandrakant Badakh Special 285,029 0

Auditor Appointment Details

The shareholders approved the appointment of M/s Panchal S K & Associates as the Statutory Auditors of the company. The firm was initially appointed by the Board of Directors on September 4, 2026, and subsequently ratified by members during the AGM.

M/s Panchal S K & Associates, established in 2017 with ICAI Registration No. 145989W, is led by founder partner Swati Panchal. The firm focuses on technology-driven practices and serves clients across SMEs and larger corporates. The appointment was made under the provisions of the Companies Act, 2013, following a resolution passed by the Board.

Managing Director Re-appointment Profile

Mr. Ashish Narayan Sakalkar was re-appointed as Managing Director pursuant to Section 152(6) of the Companies Act, 2013, having retired by rotation. He holds DIN 06601011 and is not related to any other directors of the company.

Mr. Sakalkar, aged 50 years, holds a Master of Science from NMU Jalgaon and a PhD from JJT University. He also possesses a Diploma in Regulatory Affairs from the University of Delhi. His professional experience spans Industrial Chemistry, Quality Assurance, and Regulation, with a focus on business expansion and supplier negotiation.

Meeting Proceedings and Attendance

The meeting commenced at 12:30 pm with a quorum present. Mr. Rishi Upadhaya, Company Secretary and Compliance Officer, welcomed attendees and briefed them on the virtual participation guidelines issued by the Ministry of Corporate Affairs and SEBI. Mr. Ashish Narayan Sakalkar chaired the proceedings.

The Company Secretary noted that no shareholder emails were received requesting registration as speakers for the meeting. Any prior questions submitted by shareholders had already been addressed via email to their registered addresses.

Voting Mechanism and Scrutiny

Remote e-voting was available from September 26, 2026, at 9:00 am until September 28, 2026, at 5:00 pm. Members who did not vote remotely could cast their votes instantly during the AGM via the NSDL platform. Ms. Pragya Jain, a Practicing Company Secretary, served as the Scrutinizer to ensure fair and transparent vote counting.

The combined voting results, along with the Scrutinizer's report, were declared on September 30, 2026. These results have been published on the company's website and communicated to BSE Limited in compliance with Listing Regulations.

What the Numbers Show

A distinct pattern emerges in the voting data regarding director remuneration. For Items 4, 5, and 6, which involved increases in pay for the Managing Director, Whole Time Director/CEO, and Non-Executive Director respectively, the promoters and promoter group abstained entirely from voting. This resulted in only 285,029 votes being polled, representing just 3.35% of total outstanding shares, compared to over 4.5 million votes for other agenda items. This indicates that the approval for these specific pay hikes was driven solely by public non-institutional shareholders, reflecting standard corporate governance protocols where interested parties refrain from voting on their own compensation.

Historical Stock Returns for Asston Pharmaceuticals

1 Day5 Days1 Month6 Months1 Year5 Years
-0.66%-1.67%-11.46%+24.81%0.0%-22.09%

How will the newly appointed auditor, M/s Panchal S K & Associates, influence Asston Pharmaceuticals' financial reporting standards and compliance trajectory in the coming fiscal year?

What specific operational or strategic milestones has Managing Director Ashish Narayan Sakalkar outlined to justify the approved remuneration increase and drive future growth?

Given that only 3.35% of shares voted on director compensation, what does this low participation rate suggest about institutional investor engagement and potential governance risks for minority shareholders?

like15
dislike

More News on Asston Pharmaceuticals

1 Year Returns:0.00%